A Clinician’s Guide to Selective RET Inhibitors for Patients With RET-Altered Lung and Thyroid Cancers: Indications, Dosing, and Adverse Events

Download this short PDF resource summarizing approved indications, dosing, and key safety data for the selective RET inhibitors pralsetinib and selpercatinib, including guidance on monitoring for and managing adverse events.
Format: Adobe Acrobat (.pdf)
File Size: 131 KB
Released: January 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Read expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Released: January 23, 2023

On-demand webcast from a live satellite symposium at SITC 2022 on current use of IO therapy in lung cancer, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 17, 2023 Expired: January 16, 2024

Downloadable slideset from a live meeting series for endocrinologists featuring best practices for biomarker testing and the latest evidence on targeted therapies for advanced thyroid cancer, from Clinical Care Options (CCO)

person default Maria E Cabanillas, MD person default Lori J. Wirth, MD Released: January 4, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings